SCHEMBL5228861

SCHEMBL5228861

CCCCOC(=O)Nc1ccc(OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
IGF2BP2 Q9Y6M1 1/20 0.54
KCNK2 O95069 1/20 0.52
KCNK10 P57789 1/20 0.52
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PLK1 P53350 4/20 0.48
PLK3 Q9H4B4 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489932 0.83 CYP1A2 (0.59) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL5446055 0.82 IGF2BP2 (0.61) IGF2BP2KCNK2KCNK10ALDH1A1KDM4E
SCHEMBL5720784 0.80 SMN1; SMN2 (0.55) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL687475 0.80 IGF2BP2 (0.58) IGF2BP2KCNK2KCNK10ALDH1A1KDM4E
SCHEMBL27051936 0.79 IGF2BP2 (0.63) IGF2BP2KCNK2KCNK10ALDH1A1HPGD
SCHEMBL10490025 0.79 CYP1A2 (0.54) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL10489833 0.79 METAP2 (0.55) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL19778994 0.78 SMN1; SMN2 (0.53) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL4839353 0.78 PLK1 (0.67) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD
SCHEMBL2320061 0.77 SMN1; SMN2 (0.77) CYP1A2CYP2C19SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656138-A4 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-04-18 EP disclosed
EP-1656138-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
EP-1656345-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
WO-2005020899-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed
WO-2005021500-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed
EP-1000067-A1 THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME Aventis Pharma S.A. (FR) 2000-05-17 EP disclosed
WO-1999005147-A1 THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1999-02-04 WO disclosed